Our Pipeline

Oryzon Genomics is a clinical stage biopharmaceutical company that discovers, develops, and plans to commercialize novel epigenetic therapies to treat oncology and neurodegerative diseases.

Our therapeutic strategy is to treat the underlying causes of these diseases by targeting lysine specific demethylase 1 (LSD1, also known as KDM1A). LSD1 is a histone modifying enzyme that removes methyl groups, acting as an “eraser”, and thereby regulating the expression of many genes important in the onset and progression of certain diseases such as cancer and neurodegenerative disorders.

Our product candidates are in clinical and pre-clinical stages of drug development. As reflected in the chart below, our pipeline has matured to include two clinical-stage compounds: ORY-1001, our lead oncology product, in Phase I/IIA clinical trial for acute leukemia and small cell lung cancer, and ORY-2001, our candidate for CNS, in Phase IIA, as well as a compound in preclinical development for the treatment of non-oncological diseases, ORY-3001.

The Oryzon Pipeline